Your browser is no longer supported. Please, upgrade your browser.
GOVX [NASD]
GeoVax Labs, Inc.
Index- P/E- EPS (ttm)-2.03 Insider Own8.31% Shs Outstand6.33M Perf Week-0.69%
Market Cap29.14M Forward P/E- EPS next Y-1.54 Insider Trans0.00% Shs Float6.07M Perf Month-8.84%
Income-3.90M PEG- EPS next Q-0.43 Inst Own6.10% Short Float1.93% Perf Quarter-29.82%
Sales1.20M P/S24.28 EPS this Y99.70% Inst Trans1.48% Short Ratio0.26 Perf Half Y-18.46%
Book/sh3.86 P/B1.12 EPS next Y5.50% ROA-35.50% Target Price- Perf Year-74.07%
Cash/sh3.09 P/C1.40 EPS next 5Y- ROE-40.70% 52W Range2.56 - 18.20 Perf YTD28.11%
Dividend- P/FCF- EPS past 5Y- ROI-29.00% 52W High-76.26% Beta1.77
Dividend %- Quick Ratio46.40 Sales past 5Y33.60% Gross Margin- 52W Low68.75% ATR0.42
Employees8 Current Ratio46.40 Sales Q/Q-85.70% Oper. Margin- RSI (14)44.63 Volatility12.59% 10.39%
OptionableNo Debt/Eq0.01 EPS Q/Q88.50% Profit Margin- Rel Volume0.33 Prev Close4.33
ShortableYes LT Debt/Eq0.00 EarningsMay 06 AMC Payout- Avg Volume451.84K Price4.32
Recom- SMA20-2.05% SMA50-11.69% SMA200-5.13% Volume18,853 Change-0.23%
Nov-19-20Initiated Maxim Group Buy $8
Aug-04-21 09:00AM  
Jul-22-21 09:00AM  
Jul-07-21 09:00AM  
Jun-10-21 11:00AM  
Jun-07-21 09:00AM  
May-11-21 01:08PM  
May-06-21 04:00PM  
11:30AM  
Apr-26-21 09:00AM  
Apr-20-21 10:51AM  
Apr-08-21 10:25AM  
Apr-01-21 09:00AM  
Mar-23-21 04:30PM  
Mar-17-21 09:00AM  
Mar-15-21 09:00AM  
Mar-10-21 09:00AM  
Mar-04-21 09:55AM  
Mar-03-21 09:00AM  
Mar-01-21 09:00AM  
Feb-18-21 03:20AM  
Feb-11-21 02:00PM  
Feb-08-21 11:43PM  
Jan-11-21 09:00AM  
Jan-05-21 09:00AM  
Nov-30-20 09:00AM  
Nov-05-20 05:00PM  
Oct-30-20 10:08AM  
Oct-28-20 09:00AM  
Oct-26-20 10:49AM  
09:00AM  
Sep-29-20 02:00PM  
Sep-24-20 09:23PM  
Sep-15-20 09:00AM  
Sep-03-20 09:42AM  
Aug-26-20 09:00AM  
Aug-24-20 09:00AM  
Aug-13-20 09:00AM  
Aug-10-20 09:00AM  
Jul-09-20 11:42AM  
Jun-29-20 09:00AM  
09:00AM  
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against coronavirus (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; the HIV Vaccines Trial Network; Centers for Disease Control and Prevention; U.S. Department of Defense; U.S. Army Research Institute of Infectious Disease; U.S. Naval Research Laboratory; Emory University; University of Pittsburgh; Georgia State University Research Foundation; University of Texas Medical Branch; the Institute of Human Virology at the University of Maryland; the Scripps Research Institute; the Burnet Institute; American Gene Technologies International, Inc.; Viamune, Inc.; Geneva Foundation; the University of California; and Leidos, Inc. GeoVax Labs, Inc. was incorporated in 2001 and is based in Smyrna, Georgia.